USANA Health Sciences (USNA) Tops Q1 EPS by 20c; Raises Outlook

USANA Health Sciences (NYSE: USNA) reported Q1 EPS of $1.50, $0.20 better than the analyst estimate of $1.30. Revenue for the quarter came in at $219.4 million versus the consensus estimate of $198.4 million.

USANA Health Sciences sees FY2015 EPS of $6.45-$6.75, versus prior guidance of $6.40-$6.70 and the consensus of $6.68. USANA Health Sciences sees FY2015 revenue of $870-890 million, versus prior guidance of $850-870 million and the consensus of $851.35 million.

The first quarter was an excellent start to another promising year for USANA,” said Kevin Guest, USANA’s President. “Our results for the quarter were better than expected, notwithstanding the typical pressure from the Chinese New Year and continued headwinds from a strengthening U.S. dollar. As reported, our double-digit sales, earnings and customer growth during the quarter were driven by the strong momentum we continue to see across our business and higher-than-expected sales in China.

“We also recently announced plans to enter Indonesia later this year, which will mark a milestone 20th market for USANA. Indonesia represents an excellent growth opportunity for our company in a market whose middle class is expected to double over the next five years. Our team is enthusiastic about the potential of this new market opportunity in Asia, a region that continues to generate significant growth for USANA,” continued Mr. Guest.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• AT&T (T) beats earnings estimates in Q1 but revenue falls short, shares climb
• Hilton hikes 2024 earnings outlook as Q1 results beat expectations, shares up